Ranbaxy to acquire the unbranded generic business of GlaxSmithKline in Italy
Commenting on the acquisition, Malvinder Mohan Singh, CEO and MD, Ranbaxy Laboratories Ltd., said, "This acquisition of the Allen Generic business from GSK will fast track Ranbaxy's growth plans in Italy. This product portfolio complements Ranbaxy's own pipeline of products for the Italian market and will enable the Company to utilise opportunities arising from future patent expiries."
Ranbaxy's Italian operation, Ranbaxy Italia S.p.A., was incorporated in September 2005. It is currently engaged in filing Ranbaxy's portfolio of generic products with the Italian Health Authorities and plans to launch this portfolio over the coming years. Ranbaxy plans to launch its first product, 'Sertralina Ranbaxy', in May, 2006.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.